CD274 and neoplasm: In KEYNOTE-051, PD-L1-positive tumors were identified using the 22C3 antibody and defined as >1% positivity in tumor cells or any positivity in stroma3,28; however, responses were still limited (17 of 154; 11%) indicating that PD-L1 is not sufficient as a standalone biomarker3.